Bempegaldesleukin Stimulates Immune Response.
In two clinical trials, the CD122-preferential IL2 pathway agonist bempegaldesleukin increased proliferation and activation of tumor-infiltrating lymphocytes in patients with solid tumors. Despite the lack of response to the agent as a monotherapy in the first-in-human trial, patients with metastatic urothelial carcinoma in the subsequent PIVOT-02 trial did respond when the drug was combined with the PD-1 inhibitor nivolumab.